Publications
Here you will find a comprehensive collection of all publications of the Leibniz Institute of Virology up to the year 1974. Use the filter options on the left to search specifically by year, author, research unit and journal. The search field also allows you to explore specific topics.
1974 - 2025
Displaying results 1 to 10 of 13.
Search narrowed by:
Publication
| 2025
The anti-atherosclerotic effect of chronic AT1 receptor blocker treatment also depends on the ACE2/Ang(1-7)/Mas axis.
- Klersy T, Achner L, Fels B, Rezende F, Lopez M, Alenina N, Spiecker F, Stölting I, Häuser W, Reinberger T, Aherrahrou Z, Kuenne C, Vahldieck C, Matschl U, Hille S, Bader M, Brandes RP, Müller OJ, Kusche-Vihrog K, Raasch W
-
Biomed Pharmacother,
Publication
| 2025
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy.
- Tintelnot J, Paschold L, Goekkurt E, Schultheiss C, Matschl U, Santos Cruz M, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich TJ, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka S, Al-Batran SE, Reinacher-Schick A, Pink D, Bokemeyer C, Sinn M, Lindig U, Hinke A, Hegewisch-Becker S, Stein A, Binder M
-
Cancer Immunol Res,
Publication
| 2024
Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy.
- Gorgulho J, Loosen SH, Masood R, Giehren F, Pagani F, Buescher G, Kocheise L, Joerg V, Schmidt C, Schulze K, Roderburg C, Kinkel E, Fritzsche B, Wehmeyer S, Schmidt B, Kachel P, Rolling C, Götze J, Busch A, Sinn M, Pereira-Veiga T, Wikman H, Geffken M, Peine S, Matschl U, Altfeld M, Huber S, Lohse AW, Beier F, Brümmendorf TH, Bokemeyer C, Luedde T, von Felden J
-
J Exp Clin Cancer Res,
Publication
| 2024
Fetal growth restriction induced by maternal gal-3 deficiency is associated with altered gut-placenta axis.
- Xie Y, Zhao F, Wang Y, Borowski S, Freitag N, Tirado-Gonzalez I, Hofsink N, Matschl U, Plösch T, Garcia MG, Blois SM
-
Cell Death Dis,
Publication
| 2024
Incidence of microvascular dysfunction is increased in hyperlipidemic mice, reducing cerebral blood flow and impairing remote memory.
- Hernandez Torres LD, Rezende F, Peschke E, Will O, Hövener JB, Spiecker F, Özorhan Ü, Lampe J, Stölting I, Aherrahrou Z, Künne C, Kusche-Vihrog K, Matschl U, Hille S, Brandes RP, Schwaninger M, Müller OJ, Raasch W
-
Front Endocrinol (Lausanne),
Publication
| 2022
The AT1 Receptor Blocker Telmisartan Reduces Intestinal Mucus Thickness in Obese Mice.
- Nickel L, Sünderhauf A, Rawish E, Stölting I, Derer S, Thorns C, Matschl U, Othman A, Sina C, Raasch W
-
Front Pharmacol,
Publication
| 2021
Telmisartan induces a specific gut microbiota signature which may mediate its antiobesity effect.
- Beckmann L, Künstner A, Freschi ML, Huber G, Stölting I, Ibrahim SM, Hirose M, Freitag M, Langan EA, Matschl U, Galuska CE, Fuchs B, Knobloch JK, Busch H, Raasch W
-
Pharmacol Res,
Publication
| 2021
Telmisartan prevents high-fat diet-induced neurovascular impairments and reduces anxiety-like behavior.
- Huber G, Ogrodnik M, Wenzel J, Stölting I, Huber L, Will O, Peschke E, Matschl U, Hövener JB, Schwaninger M, Jurk D, Raasch W
-
J Cereb Blood Flow Metab,
Publication
| 2019
